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Juvenile Swine Surgical Alveolar Cleft Model to Test
Novel Autologous Stem Cell Therapies
Montserrat Caballero, PhD,1,* Justin C. Morse, MD,2,* Alexandra E. Halevi, MD,3 Omri Emodi, DMD,4
Michael R. Pharaon, MD,5 Jeyhan S. Wood, MD,2 and John A. van Aalst, MD, MA1
Reconstruction of craniofacial congenital bone defects has historically relied on autologous bone grafts. En-
gineered bone using mesenchymal stem cells from the umbilical cord on electrospun nanomicrofiber scaffolds
offers an alternative to current treatments. This preclinical study presents the development of a juvenile swine
model with a surgically created maxillary cleft defect for future testing of tissue-engineered implants for bone
generation. Five-week-old pigs (n = 6) underwent surgically created maxillary (alveolar) defects to determine
critical-sized defect and the quality of treatment outcomes with rib, iliac crest cancellous bone, and tissue-
engineered scaffolds. Pigs were sacrificed at 1 month. Computed tomography scans were obtained at days 0 and
30, at the time of euthanasia. Histological evaluation was performed on newly formed bone within the surgical
defect. A 1 cm surgically created defect healed with no treatment, the 2 cm defect did not heal. A subsequently
created 1.7 cm defect, physiologically similar to a congenitally occurring alveolar cleft in humans, from the
central incisor to the canine, similarly did not heal. Rib graft treatment did not incorporate into adjacent normal
bone; cancellous bone and the tissue-engineered graft healed the critical-sized defect. This work establishes a
juvenile swine alveolar cleft model with critical-sized defect approaching 1.7 cm. Both cancellous bone and
tissue engineered graft generated bridging bone formation in the surgically created alveolar cleft defect.
Introduction
Craniofacial bone defects in humans occur in 1/250live births; the most common of these defects is the
alveolar (gumline) cleft, associated with cleft lip and palate,
which occurs in *1/700 live births.1,2 Autologous bone
grafts, often obtained from noncraniofacial sources, are used
to reconstruct these defects. Historically, these harvest sites
have included tibia, rib, and most recently, the iliac crest.3
Early surgical repair of the alveolar cleft (defined as under a
year of age) was historically the standard of treatment; rib
graft was harvested and placed within the cleft defect. As
these patients matured, it became evident that early treat-
ment led to growth restriction of the surrounding craniofa-
cial skeleton and was predisposed to resorption.4 As a
consequence these patients demonstrated poorer outcomes,
requiring additional, more complex, surgeries at skeletal
maturity.5,6 Because of these concerns, an alternative strat-
egy of delaying the graft until mixed dentition (8–10 years
of age) came into favor. Cancellous bone from the iliac crest
(a marrow-based treatment, in contradistinction to rib,
which is a cortical bone-based treatment) has now become
the gold standard for treatment of the alveolar cleft.7 This
delay in treatment allows further growth of the craniofacial
skeleton, and minimizes growth restriction8; the marrow-
based treatment allows more favorable and uniform healing
of the graft implant site. Disadvantages of this treatment
include the need for a second surgical site, donor site
morbidities,9 unpredictable resorption rates,10 and the need
to delay treatment because of insufficient cancellous bone
within the iliac crest in younger patients.3 One unintended
result in this delay is persistence of an uncorrected anomaly
beyond the age of self-awareness. As the child becomes
aware of his/her facial abnormality after 5 years of age, the
anomaly increasingly defines the individual, causing po-
tentially detrimental, lifelong psychosocial impact.11,12
Bone tissue-engineered strategies offer an exciting alterna-
tive to address the gap in the current limitation of autolo-
gous bone to treat the growing craniofacial skeleton,13 and
will allow treatments without a secondary surgical site, at an
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optimal time for the child, no longer limited by the child’s
age or size. To justify the use of novel tissue-engineered
alternatives as a replacement for current human protocols,
they must be favorably compared to the current gold stan-
dard treatment of the alveolar cleft—cancellous bone
grafting—in safety and efficacy.
The development of relevant animal models is required to
extrapolate in vitro data to in vivo results for establishing
early, successful novel treatments of pediatric alveolar clefts.
Currently, murine animal models are the most common for
studying craniofacial bone defects, including the alveolar
cleft; however, there are several significant shortcomings in
rodent models, such as significant size discrepancy when
compared to humans, functional differences of the craniofa-
cial skeleton, and major dissimilarities in wound healing
rates. These deficiencies have led to slower than predicted
translation to human conditions.14,15 Though there are several
large animal models for the alveolar cleft (goat, sheep, dog,
cat, pig, and monkey), many have significant drawbacks,
including functional dissimilarities when compared to the
human craniofacial skeleton (sheep and dog models), and
expense (primate models).16–19 The swine maxillofacial
skeleton though, has multiple functional similarities to hu-
mans, largely because swine, like humans, are omnivores;
similarities include maxillary, mandibular, and temporo-
mandibular joint function; teeth and surrounding structures;
and comparable critical-sized defects and healing rates.20
Although uncommon, alveolar clefts associated with cleft lip
and palate, also congenitally occur in pigs, and resemble al-
veolar clefts in humans (Fig. 1). An added benefit to using the
swine model is the ability to test age-based treatment strate-
gies. There is an *1 month (swine) to 1 year (human)
equivalence that is derived from the timing of central/lateral
incisors and canine eruption21 and development of sexual
maturity, which occurs between 9 and 12 months in swine
and 10–12 years in humans.22 This correlation allows for
timed interventions in a swine model that correspond to well-
characterized ages for treatment in humans.23 Finally, recent
completion of the pig genome project24 is facilitating the
development of human disease models in swine that are
currently only found in mice25; consequently, development of
swine surgical models will be a key step in initiating trans-
lational studies that address human conditions. To our
knowledge, swine alveolar cleft models are reported in only
three publications,18,19,26 with a single report of a maxillary
model to assess bone resorption after onlay bone grafting.27
None of these models addresses a preclinical scenario to test
tissue-engineered stem cell therapies.
In this study, we have developed a swine alveolar cleft
model that can be used for testing of tissue-engineered
constructs for repair of the alveolar cleft and by extension,
other craniofacial bone defects. This model will also serve




This study was approved by the Institutional Animal Care
and Use Committee (IACUC) at the University of North
FIG. 1. A child with a left
unilateral complete cleft lip
and palate (A) and bilateral
cleft lip and palate (B) with
skull models of the unilateral
(D) and bilateral (E) defects
demonstrating the absence of
bone in the maxilla at the
alveolar ridge. A piglet ca-
daver demonstrates a bilat-
eral cleft lip and palate (C),
with the skull of the same
animal demonstrating ab-
sence of bone on either side
of the anterior maxillary
segment (F). Color images
available online at www
.liebertpub.com/tec
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Carolina (UNC) and North Carolina State University School
of Veterinary Medicine (NCSU). All animal care adhered to
NIH guidelines. A total of 12 pigs were used to establish a
surgical alveolar cleft model. Six cadaveric pigs, which
were freshly euthanized following completion of unrelated
studies at UNC, were utilized for surgical technique devel-
opment, including rib and iliac crest cancellous bone harvest
(Fig. 2), creation of the alveolar defect (both unilateral and
bilateral defects), and placement of the bone grafts within
the defect. The survival surgery group included six domestic
pigs obtained from the NCSU Swine Educational Unit. The
piglets were offspring of (Yorkshire · Landrace · Large
White) sows bred to (Hampshire · Duroc · Pietran) boars
and were expected to exhibit 100% heterosis. All experi-
mental animals were negative for swine reproductive and
respiratory syndrome, mycoplasma hyopneumonia, parvo-
virus, leptospirosis, hemophilus parasuis, streptococcus suis,
swine influenza, and transmissible gastroenteritis. Piglets
were marked at birth with an ear notch and tracked for
surgery at 5 weeks. Piglets were kept in a 10 · 20 foot room
with two pigs per room in a 12/12 light/dark cycle and fed
hard pellets (Labdiet Porcine Lab Grower, PMI Nutrition
Int’l., LLC). Water was added to soften the pellets for the
first 24 h after surgery. Diet enrichment included plastic
balls and twice per day combination of the following: ap-
ples, bananas, carrots, potatoes, sugar cane, peanut butter,
and dried fruit with vegetables. During the first week post-
surgery the piglets were fed with medicated 22% protein
starter feed instead of the regular feed.
Surgical protocol
Survival surgery was performed on 5- to 6-week-old
pigs weighing 10 to 17 Kg. Three swine were left untreated
to test critical-sized defects (1.0, 1.71, and 2.0 cm) and
three were used for autologous bone graft testing (rib, iliac
crest cancellous bone, and tissue-engineered grafts). Ani-
mals were anesthetized by intramuscular injection of
midazolam (0.5–1 mg/kg) and ketamine (10–20 mg/kg);
anesthesia was maintained through the procedure with
Isoflurane 0–5% Mask/ET tube. Pigs were placed in a
lateral decubitus position, and the face and oral cavity were
prepped with betadine, and draped sterilely. Marcaine
0.25% with 1:200,000 epinephrine was injected on the
ipsilateral side before defect creation, to decrease in-
traoperative pain and bleeding. An incision was made to
the upper buccal sulcus at the junction of the gingiva and
palate mucosa, allowing release of the gingiva (with buccal
mucosa) superiorly, exposing the maxilla from the central
incisor to the canine. Palate mucosa was also elevated
exposing the underlying hard palate to the midline. Once
the soft tissue was cleared from the bony landmarks, a 1 cm
area (anterior to posterior) was marked on the exposed
bone (Fig. 3A), with extension superior to the piriform
aperture, and medially to a paramedian position on the hard
palate. A reciprocating saw was used to create the osteo-
tomies, first for a 1 cm and then for a 2 cm wide cleft (Fig.
3B). Bone margin was retained over the roots of the central
incisor and the canine. All bone was cleared to the nasal
mucosa within the piriform aperture, and to a paramedian
position on the hard palate. The defect was then either left
empty or filled with autologous bone or tissue-engineered
grafts (Fig. 3C–E) and the soft tissue of the oral cavity was
closed with interrupted vicryl sutures (Fig. 3F). A com-
puted tomography (CT) scan was performed immediately
after surgery. Appropriate postoperative antibiotics (cef-
tiofur 5 mg/kg, cefazolin 22 mg/kg, or ampicillin 20 mg/kg)
and analgesia (meloxicam 0.4 mg/kg) were administered
for 5 days postsurgery. Piglets resumed normal activities
and behavior shortly after awakening from the surgical
procedure. For the first 24 h after surgery, feed pellets were
softened by adding water. After this, animals were main-
tained on a regular hard pellet diet with enrichments as
described in the Animal Methods section. Piglets were
monitored for signs of inflammation and infection during
the postoperative period and sacrificed 30 days postsurgery
by intravenous injection of 390 mg/mL pentobarbital so-
dium, dosed at 1 mL/10 lbs. CT scans were performed
following euthanasia and ITK-SNAP 3D CT software28
was used to determine volumetric bone fill, bone bridging,
and graft resorption by comparing these CT scans with the
ones performed immediately after surgery.
FIG. 2. Cadaver studies were performed on six freshly euthanized animals. (A) The surgical markings in A1 demonstrate
the site of the skin incision for rib graft harvest (1 cm) and in A2 for iliac crest cancellous bone harvest (2 cm). (B) A 5 cm
section of rib six was harvested (B1, 2) and the iliac crest was exposed for harvest of cancellous bone (the marrow within the
iliac crest, B3, 4) and prepared for implantation. Arrow in B3 points to the area of the iliac crest accessed for removal of
cancellous bone. Color images available online at www.liebertpub.com/tec
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Autologous bone treatments
Rib graft was harvested from rib number 6, using a 1 cm
incision, leaving the periosteum intact (Fig. 2A, B1–2). The
rib graft was split longitudinally and placed with the cortical
component facing outward (Fig. 3C). Iliac crest graft was
harvested using a 2 cm incision directly over the anterior
superior iliac crest; the cartilage cap of the iliac crest split
and lifted with an osteotome exposing the underlying can-
cellous bone (Fig. 2A, B3–4); bone marrow was harvested
using a curette. Sufficient cancellous bone was harvested to
fill the alveolar defect (Fig. 3D).
Poly-lactic co-glycolic acid scaffolds preparation
Nanomicrofiber scaffolds (NMFS) were created by elec-
trospinning resorbable Delta System poly-lactic co-glycolic
acid (PLGA) implants from Stryker, as previously de-
scribed.29 Briefly, PLGA implants were solubilized in 3:1 v/v
dichloromethane:dimethyl formamide at 8% wt/v concentra-
tion and electrospun at 4.4 kV/inch, with a CO2 flow rate of 1
L/min, and polymer flow rate of 0.1 mL/h. to create 1 cm
diameter scaffolds. Before cell seeding, scaffolds were ster-
ilized in 70% alcohol under UV light for 4 h and primed
with growth media for 24 h.
Mesenchymal stem cells isolation
Swine umbilical cords (UC) were harvested at the time of
birth and labeled for future identification. UC were im-
mersed in sterile phosphate-buffered saline (PBS) with
300 U/mL penicillin, 300 mg/mL streptomycin, and 0.75 mg/
mL amphotericin B and transported in ice to the laboratory.
Umbilical cords were cut into pieces and the mesenchymal
stem cells (UC MSCs) were isolated from Wharton’s Jelly
using an explant technique. MSC phenotype was confirmed
by the presence of surface markers CD105 (89%), CD90
(99%), CD73 (71%), and the absence of CD34 ( < 1%),
FIG. 3. Surgery on living ani-
mals (n = 6) involved exposure of
the unilateral maxilla using an in-
cision at the junction of the gingi-
val mucosa and palate and marking
of the osteotomy sites (A), fol-
lowed by creation of a full-thick-
ness bone defect from the central
incisor to the canine, medially ex-
tending to the nasal mucosa of the
piriform aperture, and to the mid-
line vomer of the palate (B). The
rib graft was split to fill the surgi-
cally created 1 cm defect (C); can-
cellous bone was placed into a 2 cm
defect (D); tissue-engineered scaf-
folds were stacked within the de-
fect (E). After placing each test
condition within the defect, the
wound was closed with absorbable
suture (F). Color images available
online at www.liebertpub.com/tec
SWINE ALVEOLAR CLEFT MODEL FOR TISSUE-ENGINEERED THERAPIES 901
assayed by flow cytometry, as previously described.30 Pas-
sage 0 cells were seeded at a density of 5 · 103 cells/cm2,
grown in Dulbecco’s modified Eagle’s medium (DMEM)
15% fetal bovine serum (FBS) and sub-passaged at 80%
confluence.
Cell labeling and differentiation
To identify autologous transplanted UC MSCs, cultures were
labeled with recombinant Adeno-Associated Virus (rAAV2)
System, expressing the enhanced green fluorescence protein
(eGFP) under the CMV promoter (obtained from UNC-Vector
core). Passage 1 cells were seeded onto PLGA scaffolds at a
density of 4 · 104 cells/cm diameter of scaffold. Once MSCs
reached 80% confluence, they were incubated for 45 min in
DMEM containing glutamine and 0.5 · 1010 particles/mL of
rAAV2-eGFP. After the incubation period, media was replaced
with osteogenic media ([a]-MEM basal medium supplemented
with 10% FBS, 2 mM glutamine, 100 U/mL/100mg/mL peni-
cillin/streptomycin, 10 mM b-glycerophosphate, 0.1mm dexa-
methasone, and 50mM ascorbic acid)31,32; cells were monitored
for the presence of fluorescence using a Nikon Eclipse Ti-S
inverted microscope. Cells were then seeded onto the PLGA
scaffolds and predifferentiated (osteoinduced) for 5 days, then
implanted into the swine alveolar cleft model (Fig. 3E).
Histological analysis
Fixed bone samples were decalcified in 10% HCL/EDTA
pH 7.4 for 12 h, washed with deionized water, transferred to
70% ethanol, paraffin embedded, and sectioned into 5mm
slides. Deparaffined sections were stained with hematoxy-
lin and eosin to analyze matrix architecture, inflammatory
response, bone ingrowth, and cellular organization. Immu-
nohistochemical analysis was performed in contiguous slides
using anti-eGFP antibody (Pierce OSS00005W). Antigen re-
trieval was performed with NaCitrate buffer at 98C for
40 min and endogenous peroxidase was blocked by incuba-
tion with BLOXALL for 30 min at room temperature;
samples were then incubated with primary antibody overnight
at 4C, washed with PBS-0.1% tween 20, incubated with goat
anti-rabbit peroxidase-conjugated antibodies, and developed
with Immpact NovaRED peroxidase substrate. Hematoxylin
was used for counterstaining. Samples were analyzed using a
Nikon Eclipse Ti-S inverted microscope.
Results
Cadaveric work
Six freshly euthanized cadaveric swine were used to es-
tablish surgical technique. A 1 cm incision was required to
harvest a 5 cm section of rib number 6; a 2 cm incision was
required to harvest iliac bone using standard technique to lift
the cartilaginous cap, and harvesting the cancellous bone
using a curette (Fig. 2A, B). Alveolar clefts were created
using a reciprocating saw. Both the unilateral 1 cm and 2 cm
defect were created with no evidence of bone instability.
Similarly, creation of bilateral 1 cm defects did not create
instability of the anterior maxilla; however, a bilateral 2 cm
defect resulted in central anterior maxillary segment insta-
bility, suggesting that a similar defect in surviving swine
would result in postoperative feeding problems.
Placement of rib graft, cancellous bone, and PLGA
scaffolds were performed in the 2 cm defects created in the
cadaver pigs. A 3 cm rib segment split in two and cancellous
bone from the iliac crest was sufficient to fill both the 1 cm
and a 2 cm defects (Fig. 3C, D). PLGA scaffolds placed in
the 2 cm surgically created defect required a stack of twenty
1 cm diameter scaffolds (Fig. 3E).
Surgical procedure
Six living animals were used to establish the swine al-
veolar cleft model. The procedure was performed within a
1.5-h time frame; all animals survived surgery. Piglets re-
covered normal activity within a day after surgery. For the
first 24 h after surgery, feed pellets were softened by adding
water; with this adjustment in diet, piglets were able to feed
and drink without problems shortly after surgery. During the
month-long study no infections or other healing problems
were reported for any of the subjects and all pigs gained
weight at normal rates.
Critical size defect determination
To determine the size of a critical-sized bone defect in 5-
week-old piglets, 1 cm (Fig. 4A), 1.7 cm (Fig. 4B), and 2 cm
defects (Fig. 4C) were created and left untreated for 1 month
(actual order of surgery: 1.0 cm [based on reported critical-
sized defect], 2.0 cm, followed by 1.7 cm). CT scans per-
formed at day 30 and analyzed with ITK-SNAP 3D CT
FIG. 4. One centimeter (A),
1.7 cm (B) and 2 cm (C) surgically
created alveolar cleft defects were
left untreated in separate swine
subjects, then assessed by com-
puted tomography (CT) scan at
days 0 and 30. (A–C) The day 0
defects are demonstrated with
white brackets. At day 30, 3D CT
scan reconstructions demonstrate
bridging bone in the 1 cm defect
(D) with no or minimal evidence of
bone healing in the 1.7 and 2 cm
defects (E, F; the blue color des-
ignates absent bone). Arrow des-
ignates the extent of the original
defect. Color images available on-
line at www.liebertpub.com/tec
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software demonstrated complete healing of the 1 cm defect
with bone bridging (Fig. 4D), while the 1.7 and 2 cm defect
showed a nonhealed bone gap (Fig. 4E, F). Piglet weight,
defect size, and normalized defect size by weight for all the
experimental subjects are listed in Table 1.
Bone formation and volume fill
One month after surgery the CT scans obtained from a
normal maxilla (Fig. 5A, D) were compared to defects
treated with rib (Fig. 5B, E) and cancellous bone (Fig. 5C,
F); the rib graft did not demonstrate integration with sur-
rounding, intact maxilla (Fig. 5E); the cancellous graft in-
tegrated with the surrounding tissue with bridging bone
formation detected in the alveolar defect (Fig. 5F). New
bone formation and integration with surrounding maxillary
bone was also detected at day 30 postsurgery in the defect
treated with autologous UC MSC-PLGA implants, as shown
in the 3D reconstruction of the CT scan in Figure 6D.
Bone volume calculations were performed using ITK-
SNAP software for the cancellous bone (Fig. 6A, C) and UC
MSC-PLGA (Fig. 6B, D)-treated defects. The defect treated
with UC MSC-PLGA scaffolds showed a slightly better
volume fill of the defect, with 37 mm3/kg (589 mm3 total)
compared with 22 mm3/kg (389 mm3 total) for the cancel-
lous bone graft (Fig. 6E).
Histology
Bone formation was evaluated with H&E staining of tissue
sections from the treated defects. None of the histological
sections demonstrated signs of inflammatory reaction. The rib
graft appeared as resorbing compact bone with a rim of os-
teoclasts surrounding the implanted bone (Fig. 7B); the
cancellous bone and the UC MSC-PLGA grafts showed
evidence of immature bone formation (Fig. 7C, D), with
structural similarity to normal maxillary bone (Fig. 7A) with
osteoid, connective tissue, and trabeculations. Immuno-
staining with anti-GFP antibody revealed the presence of
differentiated labeled cells implanted within the UC MSC-
PLGA scaffolds associated with the newly generated bone
(Fig. 7 E, F).
Discussion
Current surgical techniques for early repair of the alveolar
cleft have severe limitations including growth restriction,
implant reabsorption, and the need for staged, multiple
surgical procedures.4–7 Delayed repair of the alveolar cleft
using cancellous bone from the iliac crest has eliminated
growth restriction, but it still requires a secondary surgical
site.7 Tissue-engineered strategies offer a promising alter-
native to the current treatment strategy, but require proof of
equivalence to the current gold standard treatment (or evi-
dence of improved efficacy), and safety, both in vitro, and in
large animal models, before translation to humans.
Swine models are currently being used in multiple med-
ical and surgical disciplines,33–36 suggesting that swine
models as a proxy for human conditions are reasonable.
Further benefits to the use of swine, include recent com-
pletion of the swine genome project, with steady increases
in the number of swine transgenic models,37,38 including a
green fluorescent protein model39 and a severe combined
immunodeficiency model40; these models yield exciting
possibilities for preclinical trials in swine that were previ-
ously limited to rodent and primate models.37,41–43
Anatomic similarities between swine and humans in body
size, maxillary bone anatomy, TMJ function23; bone re-
modeling, regeneration, and cortical bone mineralization,
and critical-sized bone defects,44 also suggest that swine
craniofacial models that mimic human conditions are also
appropriate. Several swine models exist for use in cranio-
facial conditions including mandibular reconstruction,33
post traumatic conditions,36 cranial defects,35 and nasal and
Table 1. Weight-Based Critical-Sized Defects














1 cm untreated 1.0 17 31 0.06
2 cm untreated 2.0 10.8 17.5 0.19
1.7 cm untreated 1.7 10 23 0.17
Rib graft 1.0 14 28.5 0.07
Cancellous graft 2.0 11.9 17 0.17
UC MSC-PLGA 1.5 9 18 0.17
Because weight significantly varied for 5-week-old piglets, a
normalized defect size was established. Normalization was weight
based, and created based on the knowledge that the 2 cm defect in a
pig weighing 10.8 kg did not heal. (a) normalized ratio of 0.17 cm/kg.
PLGA, poly-lactic co-glycolic acid; MSC, mesenchymal stem
cell; UC, umbilical cords.
FIG. 5. Day 30 CT scans demon-
strate normal swine maxilla (A, D)
compared to a 1 cm surgically cre-
ated defect treated with rib graft (B,
E) and a 2 cm defect treated with
cancellous bone (C, F). Rib graft (E)
exhibited lack of integration to the
surrounding normal bone (denoted
by the arrows), while cancellous
bone graft (F) demonstrated bridg-
ing bone (arrows) with integration
into the surrounding normal bone.
Brackets clarify the location of the
bone defect. Color images available
online at www.liebertpub.com/tec
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oral reconstruction34; however, only a single study has used
a swine model to study a critical-sized maxillary defect,
which was treated with distraction osteogenesis.45 Our study
describes the creation of a critical-sized maxillary defect in
swine to test novel tissue-engineered therapies.
The human alveolar cleft uniformly occurs in continuity
with a cleft of the lip. To mimic this condition exactly in the
swine model would have necessitated creating both a cleft
lip and alveolus simultaneously. However, concurrent de-
fects in the soft tissue and bone would have resulted in a
healing conundrum: closing the newly created soft tissue
defect would result in scar tissue, which would have an
immediate impact on the healing of alveolar cleft treat-
ments. Leaving the soft tissue defect unrepaired would
similarly impact the healing of a treated bone defect. To
limit variables affecting treatment of the bone defect, the
decision was made to create the bone defect in isolation.
Secondarily, a decision was made to use a unilateral alveolar
defect rather than a bilateral defect. The pig is an obligate
nasal breather; bilateral defects could theoretically result in
inflammatory changes in both nostrils, resulting in ob-
struction leading to an inability to breathe postoperatively.
In addition, the instability of the central maxillary segment
with bilateral defects approaching 2 cm in size would have
caused postoperative feeding problems and impeded bone
healing, which requires stability of the surrounding bone
structures. The bilateral 1 cm defect—which did not result in
maxillary instability—healed without treatment in the first
test animal, and hence was not pursued.
The 1 cm surgically created alveolar cleft defect was
chosen because this is the reported dimension of a critical-
sized defect in swine22; however, this defect healed during
FIG. 6. CT scans demonstrate the
surgically created defects at days 0
(A, B) and 30 (C, D) with new
bone generation highlighted in
yellow after treatment with cancel-
lous bone (C) and differentiated
UC MSCs on PLGA scaffolds (D).
This reconstruction represents a
single vertical cut through the
bone, and hence only provides a 2D
surface area of new bone forma-
tion. The total volume of newly
generated bone was determined
using ITK Snap software (E). UC
MSC graft treatment resulted in a
larger volume of new bone forma-
tion than cancellous bone treat-
ment, in both absolute volume
(solid bars) and volume normalized
by weight (hashed bars). PLGA,
poly-lactic co-glycolic acid; MSC,
mesenchymal stem cell; UC, um-
bilical cords. Brackets clarify the
location of the bone defect. Color
images available online at www
.liebertpub.com/tec
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the 1-month evaluation period. This finding was not alto-
gether surprising because juveniles have greater healing
capacity than adults, both in swine and in humans.46,47 The
2 cm defect was chosen as a larger sized defect that would
not compromise maxillary stability (as determined by our
cadaver work). Though this defect did not heal, the size of
this defect was problematic in smaller piglets. Because of
variation in the size of 5-week-old piglets (with weight
variations from 9.0–17 kg), a 2 cm defect would involve a
significant portion of the hemi maxilla, and it would be well
beyond the borders of a congenitally occurring alveolar cleft
defect in both humans and pigs (which should extend from
the central incisor to the canine; Fig. 1). Given these con-
siderations, our next surgically created defect was made as
large as possible, but maintained between the central incisor
and canine. This defect size was 1.71 cm in a 10 kg pig. To
create standardized defects in pigs, normalizing for weight
is a logical choice because pig weight gain correlates di-
rectly to maxillary size,22 a finding that was confirmed in
our cohort of piglets (data not shown). Given that the
1.71 cm defect in a 10 kg pig was critical sized the re-
mainder of the study animals underwent creation of defects
that were 0.17 cm/kg (Table 1).
To compare treatment outcomes, we utilized rib graft (his-
torical treatment), cancellous bone graft (current gold standard
treatment), and UC MSC-PLGA NMFS (a novel tissue-
engineered construct). In our juvenile swine model, the rib
graft did not integrate with the surrounding tissue; histological
FIG. 7. H&E stains comparing
contralateral normal maxilla (A)
with rib (B), cancellous bone (C),
and UC MSC-PLGA grafts (D)
demonstrate absorbing cortical
bone with a rim of osteoclasts, and
nonintegration in the rib graft (B).
The cancellous graft (C) and
UCMSC-PLGA (D) demonstrate
normal appearing bone formation.
To determine the presence of UC
MSCs in the newly formed bone,
normal maxilla (E) was compared
to the newly formed bone with UC
MSCs labeled with AAv-GFP (F).
GFP-positive cells (stained in red)
are present in the areas of new bone
formation within the treated defect,
indicating the presence of im-
planted UC MSCs; no background
staining is noted in normal bone.
Pictures shown for treatments cor-
respond to the center of the defect.
No host bone is shown. Color
images available online at
www.liebertpub.com/tec
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analysis revealed compact mature bone (still present from the
original implanted rib) with osteoclasts lining the surface of
the graft, a signal of bone reabsorption. This finding corrob-
orates historical problems associated with this treatment in
humans, including lack of integration and bone reabsorption.3
Cancellous bone grafting is the current gold standard
treatment for the human alveolar cleft. This is a marrow-
based treatment that results in improved bone generation
and retention in the cleft.48 Treatment of the surgically
created alveolar cleft defect with cancellous bone graft
demonstrated integration with the surrounding bone and
appropriate volume filling of the defect. Histological ex-
amination demonstrated woven, immature bone resembling
the surrounding intact maxillary bone and correlates with
findings in humans.48,49
The alveolar cleft is a relatively limited bone defect, but it
is representative of many other larger craniofacial bone
defects. If an engineered bone protocol can be determined as
safe and efficacious for the alveolar cleft, it will have far-
reaching consequences for treatment of a variety of cra-
niofacial defects. The immediate benefit of our approach
using autologous UC MSCs on PLGA electrospun NMFS is
that UC harvest is both noninvasive and noncontroversial,
yielding a high number of plastic MSCs.50 The value of
these MSCs is currently being tested worldwide in 55 open
clinical trials using transplantation or infusion protocols for
diseases including diabetes mellitus, Alzheimer’s disease,
acute burn, liver cirrhosis, and cardiomyopathy.51 Further-
more, a limited but growing literature examining porcine
MSCs has demonstrated function similar to human MSCs.52
The scaffolds used in our studies were electrospun from
Stryker Delta resorbable plates (PLGA), which are FDA ap-
proved for use in pediatric patients. These plates are both
nonimmunogenic and biodegradable. We have previously
demonstrated that these electrospun scaffolds support MSC
attachment, migration, proliferation, osteogenic differentia-
tion, and matrix deposition30,53; work by others has demon-
strated adequate structural support for treating bone defects
in vivo.54,55 In this study, bone generated using differentiated
UC MSCs on PLGA NMFS was better (though not statisti-
cally significant) by CT volumetric analysis and histologi-
cally similar to the bone generated using cancellous bone
from the iliac crest. In the tissue-engineered treatment, his-
tology demonstrated no evidence of reabsorption or inflam-
mation within the graft site. The preliminary indication, based
on the anti-GFP antibody findings, is that the differentiated
UC MSCs are present and contribute to bone formation
within the surgically created cleft. Taken together, these
findings suggest that autologous UC MSC-based tissue-
engineered scaffolds are a promising treatment option for the
alveolar cleft.
There are some limitations to our findings. A more critical
examination of the CT scan demonstrates incomplete fill of
the cleft with newly generated bone. Because complete
bridging bone across the cleft is the desired outcome of our
study, we need to develop strategies to improve bone fill of
the defect. The change to our protocol most likely to gen-
erate this improvement is an increased time course of
healing. We are currently performing studies that will allow
follow-up of 3 and 6 months to allow maturation of newly
developed bone. Increased duration of the study will also
improve the accuracy of 3D CT software analysis. ITK-
SNAP 3D reconstruction software is based on attenuation
labeling, which is directly related to calcium content of the
bone; the ability to differentiate bone from surrounding soft
tissue increases as bone matures. Lastly, the sample size of
our study is limited; studies we have already initiated will
include a larger number of piglets to establish statistical
differences between treatment strategies.
Previous MSC treatments in swine models has demon-
strated benefit for myocardial infarction56 and defects in
articular cartilage57; however, there are no published reports
of autologous porcine UC MSCs to treat bone defects. Al-
though based on a small sample size secondary to the high
cost of swine subjects, our preliminary study is the first to
demonstrate use of autologous UC MSCs for bone regen-
eration in vivo. In addition, our study is the first to reveal
successful bone regeneration in a critical-sized maxillary
defect with use of predifferentiated MSCs.
Conclusions
A novel, reproducible, critical-sized alveolar cleft swine
model is presented with three treatment alternatives in-
cluding a successful tissue-engineered treatment with UC
MSCs on PLGA NMFS. The swine model appears to be a
strong platform for in vivo testing of engineered bone, with
the novel therapy favorably comparing to cancellous bone
grafting, the current gold standard treatment. To prepare the
foundation for clinical studies using UC MSCs, we are now
expanding the number of test animals, and extending the
time frame for follow-up. This strategy should give us more
definitive evidence of the efficacy of this novel stem cell-
based treatment.
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